search
Back to results

Possible Links Between Inflammation and Lipid Metabolism

Primary Purpose

Sepsis, Inflammation, LPS

Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
LPS infusion
Sponsored by
Barmherzige Brüder Linz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sepsis

Eligibility Criteria

18 Years - 40 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Men aged 18 to 40 years
  • Written informed consent
  • No disease history
  • non-smoker
  • BNP level within the normal range
  • Normal renal function (serum creatinine of 1.3 mg/dL and/or creatinine clearance greater than 80ml/min)

Exclusion Criteria:

  • Systolic blood pressure < 90 mmHg
  • Subjects on any medication
  • History of anaphylaxis
  • Probands who suffer from infectious disease

Sites / Locations

  • Barmherzige Brüder Linz - Innere Medizin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

LPS infusion

Placebo

Arm Description

infusion of LPS 2 ng/kg over 5 minutes

NaCl

Outcomes

Primary Outcome Measures

lipid kinetics
levels of lipid parameters including LDL, HDL, lipoprotein(a), apolipoprotein A1 and apoB will be measured at multiple timepoints (t0, t15, t30, t60, t120, t180, t360, 24h and 48h) in order to evaluate the detaile kinetics of lipid parameters in inflammatory condidtions

Secondary Outcome Measures

Full Information

First Posted
December 21, 2017
Last Updated
October 16, 2018
Sponsor
Barmherzige Brüder Linz
search

1. Study Identification

Unique Protocol Identification Number
NCT03392701
Brief Title
Possible Links Between Inflammation and Lipid Metabolism
Official Title
Possible Links Between Inflammation and Lipid Metabolism
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
December 20, 2017 (Actual)
Primary Completion Date
July 30, 2018 (Actual)
Study Completion Date
September 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Barmherzige Brüder Linz

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
It has been recognized lately that sepsis and inflammation has an important impact on lipid metabolism and that the extent of hypocholesterolemia may even be a marker of severity of illness. However, the interplay between inflammation and the marked changes in lipid metabolism remain to be sufficiently understood. Importantly, the exact kinetics of lipid parameters in inflammatory conditions are yet to be explored. This study aims to investigate the interaction between inflammation and lipid metabolism using the human endotoxin model (LPS infusion) in ten healthy volunteers in a single blinded randomized placebo controlled cross-over design.
Detailed Description
Sepsis is a severe clinical syndrome with still limited means of therapy and often poor prognosis. It has been recognized lately that sepsis and inflammation has an important impact on lipid metabolism and that the extent of hypocholesterolemia may even be a marker of severity of illness. This study aims to investigate the interaction between inflammation and lipid metabolism and the possible role of various markers of lipid metabolism including apolipoprotein B, apoA1 and lipoprotein(A) using the human endotoxin model in ten healthy volunteers. In this model, volunteers are infused intravenously with bacterial lipopolysaccharide (LPS, 2 ng/kg over 5 minutes) to simulate human sepsis. Immediately after the infusion of LPS, proinflammatory cytokines and other mediators are elevated just as they are in common sepsis. This widely used model thus represents a reliable method for evaluating conditions during inflammation. In this study, LPS will be administered to ten healthy male volunteers aged 18-40 years and plasma levels of lipid parameters including those described above will subsequently be measured repeatedly to evaluate the influence of LPS on lipid metabolism and detailed kinetics of lipid parameters. This project is planned as a prospective, single blinded randomized, placebo controlled cross-over study. Participants must be free of disease history and previous anaphylactic events, must not be on any medication and will be screened for medical disorders including renal, hepatic and cardiovascular conditions, thrombophilia and infections in an initial medical examination. Each participant will be studied on two different study days with a washout period of at least 14 days, on which either LPS (National Reference Bacterial Endotoxin, lot EC-6, prepared from Escherichia coli 0113, USPC, Inc. Rockville, MD) and saline or saline alone as a placebo will be administered. LPS will be infused in a dosage of 2 ng/kg over a period of 5 minutes. Participants will be studied after an overnight fast and after 24 hours without smoking and without consumption of caffeine-containing beverages in order to ensure standard baseline conditions. During the study, subjects will rest in a supine position. Infusion and sampling will be done using two separate intravenous catheters. Blood samples will be centrifuged, transferred into chilled tubes and placed on ice. Plasma will be frozen at -80°C until it will be assayed. Plasma and urine sodium, potassium, creatinine and glucose will be measured via routine laboratory techniques. A case record form will be completed for each volunteer and data will subsequently be handled in an anonymous manner. Data will be analysed using repeated measures ANOVA. In summary, this study aims to evaluate the interactions between sepsis and lipid metabolism using the human endotoxin model. Such knowledge could improve the understanding of the pathophysiology in sepsis and may lead to the development of novel therapeutic strategies. Insights on possible interactions between inflammation and lipid metabolism could also enlighten pathophysiological pathways in metabolic syndrome and type 2 diabetes mellitus causing chronic low-grade inflammation with potential impact on various medical fields.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Inflammation, LPS, Lipid Metabolism Disorder

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LPS infusion
Arm Type
Experimental
Arm Description
infusion of LPS 2 ng/kg over 5 minutes
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
NaCl
Intervention Type
Biological
Intervention Name(s)
LPS infusion
Intervention Description
infusion of LPS 2 ng/kg over 5 minutes
Primary Outcome Measure Information:
Title
lipid kinetics
Description
levels of lipid parameters including LDL, HDL, lipoprotein(a), apolipoprotein A1 and apoB will be measured at multiple timepoints (t0, t15, t30, t60, t120, t180, t360, 24h and 48h) in order to evaluate the detaile kinetics of lipid parameters in inflammatory condidtions
Time Frame
48 hours

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men aged 18 to 40 years Written informed consent No disease history non-smoker BNP level within the normal range Normal renal function (serum creatinine of 1.3 mg/dL and/or creatinine clearance greater than 80ml/min) Exclusion Criteria: Systolic blood pressure < 90 mmHg Subjects on any medication History of anaphylaxis Probands who suffer from infectious disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthias Heinzl, MD
Organizational Affiliation
Barmherzige Brüder Linz
Official's Role
Study Chair
Facility Information:
Facility Name
Barmherzige Brüder Linz - Innere Medizin
City
Linz
ZIP/Postal Code
4021
Country
Austria

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35616594
Citation
Heinzl MW, Resl M, Klammer C, Fellinger P, Schinagl L, Obendorf F, Feldbauer R, Pohlhammer J, Wagner T, Egger M, Dieplinger B, Clodi M. SUBCLINICAL KIDNEY INJURY IS CAUSED BY A MODERATE SINGLE INFLAMMATORY EVENT. Shock. 2022 Jul 1;58(1):14-19. doi: 10.1097/SHK.0000000000001942. Epub 2022 Jul 19.
Results Reference
derived
PubMed Identifier
34273987
Citation
Millischer V, Heinzl M, Faka A, Resl M, Trepci A, Klammer C, Egger M, Dieplinger B, Clodi M, Schwieler L. Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial. J Neuroinflammation. 2021 Jul 17;18(1):158. doi: 10.1186/s12974-021-02196-x.
Results Reference
derived
PubMed Identifier
31843964
Citation
Heinzl MW, Resl M, Klammer C, Egger M, Dieplinger B, Clodi M. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response. Infect Immun. 2020 Feb 20;88(3):e00842-19. doi: 10.1128/IAI.00842-19. Print 2020 Feb 20.
Results Reference
derived

Learn more about this trial

Possible Links Between Inflammation and Lipid Metabolism

We'll reach out to this number within 24 hrs